Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials

To evaluate the safety of daily oral ospemifene 60 mg, estrogen agonist/antagonist, used to treat moderate-to-severe dyspareunia due to postmenopausal vulvovaginal atrophy, which is part of genitourinary syndrome of menopause. Post hoc analysis of safety data (treatment-emergent adverse events [TEAE...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of women's health (Larchmont, N.Y. 2002) N.Y. 2002), 2018-01, Vol.27 (1), p.14-23
Hauptverfasser:	Simon, James A, Altomare, Corrado, Cort, Susannah, Jiang, Wei, Pinkerton, JoAnn V
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!